Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ronald A. Salerno"'
Autor:
James F. Kelly, Ronald A Salerno, Kevin Carl, Brian B Spear, Lois Hinman, Brian M. Abbott, Courtney Harper, Elizabeth Mansfield, Stephen P. Day, Russell Katz, Robert L. Becker, Michael Pacanowski, William Pignato
Publikováno v:
Pharmacogenomics. 11:1669-1675
At the 5th FDA–Drug Industry Association (DIA) Workshop on ‘Pharmacogenomics in Drug Development and Regulatory Decision Making’, track four focused on the current thinking and issues in the co-development of therapeutic drugs or biologics, and
Publikováno v:
Pharmacogenomics. 10:111-115
The 4th US FDA/Industry workshop, in a series on Pharmacogenomics, was on ‘Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making’ and was held on December 10–12, 2007 in Bethesda, MD, USA, with clear objectives to c
Autor:
Ronald A Salerno, Lawrence J. Lesko
Publikováno v:
The Pharmacogenomics Journal. 6:78-81
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop
Autor:
Lawrence J. Lesko, Ronald A Salerno
Publikováno v:
Pharmacogenomics. 5:25-30
Autor:
A McCarthy, D M Barnes, Mark Watson, Duncan McHale, CE Lister, K Cheeseman, J Friedman, B B Spear, Celia Brazell, Ronald A Salerno, D C Anderson, SC Ray, Peter M. Shaw, Nadine Cohen, Lara Hashimoto, Baltazar Gomez-Mancilla, R Sandbrink
Publikováno v:
The Pharmacogenomics Journal. 2:284-292
Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group
Autor:
Ronald A Salerno, Lawrence J. Lesko
Publikováno v:
Pharmacogenomics. 5:503-505
2004 © Future Medicine Ltd IS The FDA/DIA/PWG/PhRMA/BIO workshop on ‘Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal’ was held in Washington DC in November last year to focus on the
Autor:
Joanne M. Killinger, Timothy Anderson, Ronald A Salerno, Elizabeth Mansfield, Susan Ide, Stephen G Ryan, Baltazar Gomez-Mancilla, Shiew-Mei Huang, Frank D. Sistare, Lawrence J. Lesko, Alexandra Worobec, John K. Leighton, Donald C. Anderson, Joseph L. Hackett, Virginia D. Schmith, Jerry M. Collins, Brian B Spear, Peter M. Shaw, David M. Essayan, Andrew J Dorner, Celia Brazell, Robert J. Meyer, Mark Watson
The use of pharmacogenetics and pharmacogenomics in the drug development process, and in the assessment of such data submitted to regulatory agencies by industry, has generated significant enthusiasm as well as important reservations within the scien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::986fccba730d4ebef95ac6b614ae230e
https://zenodo.org/record/1235536
https://zenodo.org/record/1235536
Autor:
Lawrence J. Lesko, Ronald A. Salerno, Brian B. Spear, Donald C. Anderson, Timothy Anderson, Celia Brazell, Jerry Collins, Andrew Dorner, David Essayan, Baltazar Gomez-Mancilla, Joseph Hackett, Shiew-Mei Huang, Susan Ide, Joanne Killinger, John Leighton, Elizabeth Mansfield, Robert Meyer, Stephen G. Ryan, Virginia Schmith, Peter Shaw
Publikováno v:
Journal of Clinical Pharmacology; Apr2003, Vol. 43 Issue 4, p342-358, 17p
Publikováno v:
Experimental Biology and Medicine. 160:18-23
SummaryInjection of high doses of KT-FeLV feline leukemia virus produced both viremia and leukemia in a portion of 1- to 2-day-old kittens but not in 17- to 24-week-old animals. Contact of susceptible cats with infected cagemates did not result in vi